What is ReceptivaDx?
ReceptivaDx is the only test that can identify endometriosis, progesterone resistance and endometritis in a single sample. ReceptivaDx includes BCL6, a marker that identifies uterine inflammation most often associated with asymptomatic (silent) endometriosis. BCL6 is found in more than 50% of women with unexplained infertility and 65% of women with two or more IVF failures. The ability to identify progesterone resistance via the BCL6 marker has been previously linked in published data to both implantation failure and recurrent pregnancy loss. Progesterone resistance is a condition that causes unfavorable changes on the uterine lining blocking the important hormone progesterone from carrying out its vital role in preparing the lining for embryo survival. Finally, ReceptivaDx can also be used to identify endometritis (chronic bacterial infection of the uterine lining) via the addition of our CD138 marker. The good news for providers and patients is that a positive BCL6 or CD138 result both have effective treatment options, significantly improving chances for a live birth.
If the test results are positive, it indicates a high level of BCL6, identifying the presence of uterine lining inflammation, most often associated with endometriosis. If the test results are negative, it suggests a high likelihood that no inflammation is present, Either results are useful to you and your physician because they narrow down potential courses of action, increasing your chances of a successful live birth.
How can the ReceptivaDx test help me?
If endometriosis goes untreated, issues with fertility are likely to persist, even throughout IVF treatment. Women who test positive for BCL6 and left untreated are 5 times less likely to succeed in IVF than women who test negative.
If positive, there are two courses of action that have proven effective in thousands of IVF patients; hormone treatment to suppress the inflammation or laparoscopic surgery to remove the problematic tissue. Removing endometriosis around the endometrial lining has also proven to increase the chances of conception even without IVF.
A negative BCL6 test result provides the reassurance that endometriosis is not a current concern and that future attempts at pregnancy are more likely to be successful.
While other tests evaluate the quality of embryos or determine optimal embryo transfer windows, only ReceptivaDx™ can accurately detect inflammatory conditions on the uterine lining likely to cause implantation issues. If you have experienced infertility, ReceptivaDx test results can give you peace of mind, a clear plan for treatment, and renewed chances of a successful pregnancy.
ReceptivaDx™ (BCL6 Test) Predicts Chances for a Successful Transfer and Successful Pregnancy
In a study published in the December 2017 issue of Fertility & Sterility, the official journal of the American Society of Reproductive Medicine (ASRM), BCL6 was able to identify women with a poor prognosis for IVF success and a successful pregnancy if left undetected and untreated. Endometrial BCL6 testing for the prediction of in vitro fertilization outcomes: a cohort study. Almquist LD, Likes CE, Stone B, Brown KR, Savaris R, Forstein DA, Miller PB, Lessey BA Fertil Steril. 2017 Dec;108(6):1063-1069
Women testing positive for ReceptivaDx (BLC6) without treatment:
- Less than 11% Success rate resulting in live birth
Women testing negative for ReceptivaDx (BLC6):
- More than 59% Success rate resulting in live birth
Without treatment, women testing positive are 5 times less likely to succeed in IVF.
Frequently Asked Questions
Get started and get answers. Find a center near you with our locator map. Questions? Call us for a free phone consultation. We’re here to help.